Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: A retrospective analysis of 12 cases

Cancer

Volumn 112, Issue 4, 2008, Pages 885-891

  Kiyota, Naomi ^a   Tahara, Makoto ^a   Fujii, Satoshi ^a   Kawashima, Mitsuhiko ^a   Ogino, Takashi ^a   Minami, Hironobu ^a   Hayashi, Ryuichi ^a   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; Docetaxel; Irinotecan; Olfactory neuroblastoma; Proton radiotherapy

Indexed keywords

DOCETAXEL; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ESTHESIONEUROBLASTOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; METASTASIS; NEUTROPENIA; PHOTON THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; ESTHESIONEUROBLASTOMA, OLFACTORY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROBLASTOMA; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 39049092407     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23246     Document Type: Article

References (39)

1. Kadish SGM, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976;37:1571-1576.
2. Elkon D, Hightower SI, Lim ML, Cantrell RW, Constable WC. Esthesioneuroblastoma. Cancer. 1979;44:1087-1094.
3. McCormack LJ, Harris HE. Neurogenic tumors of the nasal fossa. JAMA. 1955;157:318-322.
4. Berger L, Luc R. L'esthesioneroepitheliome olfactif. Bull Assoc Franc Etude Cancer. 1924;13:410-421.
5. Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997;17:2683-2706.
6. Spaulding CA, Kranyak MS, Constable WC, Stewart FM. Esthesioneuroblastoma: a comparison of 2 treatment eras. Int J Radiat Oncol Biol Phys. 1988;15:581-590.
7. Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, Westra WH. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck. 2000;22:550-558.
8. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001;2:683-690.
9. Austin JR, Cebrun H, Kershisnik MM, et al. Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the M.D. Anderson Cancer Center. Skull Base Surg. 1996;6:1-8.
10. Foote RL, Morita A, Ebersold MJ, et al. Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1993;27:835-842.
11. Zappia JJ, Carroll WR, Wolf GT, Thornton AF, Ho L, Krause CJ. Olfactory neuroblastoma: the results of modern treatment approaches at the University of Michigan. Head Neck. 1993;15:190-196.
12. Diaz EM Jr, Johnigan RH 3rd, Pero C, et al. Olfactory neuroblastoma: the 22-year experience at 1 comprehensive cancer center. Head Neck. 2005;27:138-149.
13. Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg. 1997;123:34-40.
14. Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002;94:2623-2634.
15. Levine PA, Gallagher R, Cantrell RW. Esthesioneuroblastoma: reflections of a 21-year experience. Laryngoscope. 1999;109:1539-1543.
16. Miyamoto RC, Gleich LL, Biddinger PW, Gluckman JL. Esthesioneuroblastoma and sinonasal undifferentiated carcinoma: impact of histological grading and clinical staging on survival and prognosis. Laryngoscope. 2000;110:1262-125.
17. Simon JH, Zhen W, McCulloch TM, et al. Esthesioneuroblastoma: the University of Iowa experience 1978-1998. Laryngoscope. 2001;111:488-493.
18. McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery.42:1023- 107, 1998; discussion 27-8.
19. Sheehan JM, Sheehan JP, Jane JA, Polin RS. Chemotherapy for esthesioneuroblastomas. Neurosurg Clin N Am. 2000;11:693-701.
20. Goldsweig HG, Sundaresan N. Chemotherapy of recurrent esthesioneuroblastoma. Case report and review of the literature. Am J Clin Oncol. 1990;13:139-143.
21. Wade PM Jr, Smith RE, Johns ME. Response of esthesioneuroblastoma to chemotherapy. Report of 5 cases and review of the literature. Cancer. 1984;53:1036-1041.
22. Eriksen JG, Bastholt L, Krogdahl AS, Hansen O, Joergensen KE. Esthesioneuroblastoma - what is the optimal treatment? Acta Oncol. 2000;39:231-235.
23. Yoh K, Tahara M, Kawada K, et al. Chemotherapy in the treatment of advanced or recurrent olfactory neuroblastoma. Asia-Pac J Clin Oncol. 2006;2:180-184.
24. Nishimura H, Ogino T, Kawashima M, et al. Proton-beam therapy for olfactory neuroblastoma. Int J Radiat Oncol Biol Phys. 2007;68:758-762.
25. Kawada K, Sasaki Y, Tahara M, et al. Phase I and pharmacokinetic study of weekly docetaxel (DOC) plus irinotecan (IRN) in patients with advanced solid tumors. Proc Amer Assoc Cancer Res. 2005;46:938.
26. Silva EG, Butler JJ, Mackay B, Goepfert H. Neuroblastomas and neuroendocrine carcinomas of the nasal cavity. Cancer. 1982;50:2388-2405.
27. Mills SE, Frierson HF. Olfactory neuroblastoma: a clinicopathologic study of 21 cases. Am J Surg Pathol. 1985;9:317-327.
28. Hyams V, Batsakis J, Michaels L. Tumors of the Upper Respiratory Tract and Ear. 2nd ed. Vol. 25. Washington, DC: Armed Forces Institute of Pathology; 1988.
29. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
30. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993;32:706-714; discussion 14-5.
32. Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope. 1990;100:1199-1201.
33. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. 1992;102:843-849.
34. Polin RS, Sheehan JP, Chenelle AG, et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery. 1998;42:1029-1037.
35. Chao KS, Kaplan C, Simpson JR, et al. Esthesioneuroblastoma: the impact of treatment modality. Head Neck. 2001;23:749-757.
36. Kim DW, Jo YH, Kim JH, et al. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer. 2004;101:2257-2260.
37. Mishima Y, Nagasaki E, Terui Y, et al. Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with esthesioneuroblastoma. Cancer. 2004;101:1437-1444.
38. Levine PA, Debo RF, Meredith SD, Jane JA, Constable WC, Cantrell RW. Craniofacial resection at the University of Virginia (1976-1992): survival analysis. Head Neck. 1994;16:574-577.
39. Richtsmeier W, Briggs R, Koch W. Complications and early outcome of anterior craniofacial resection. Arch Otolaryngol Head Neck Surg. 1992;118:913-917.